eISSN: 2084-9834
ISSN: 0034-6233
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank

vol. 60
Original paper

Routine IgG4 staining in minor salivary gland biopsy in a cohort of Italian Caucasian patients suffering from xerostomia

Edoardo Conticini
Roberto D’Alessandro
Marco Bardelli
Paolo Falsetti
Stefano Gentileschi
Virginia Mancini
Luca Cantarini
Bruno Frediani

Department of Medicine, Surgery, and Neurosciences, Rheumatology Unit, University of Siena, Italy
Department of Medical Biotechnology, Section of Pathology, University of Siena, Italy
Reumatologia 2022; 60, 1: 12 –15
Online publish date: 2022/02/28
Article file
- Routine IgG4.pdf  [0.08 MB]
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero


IgG4-related disease (IgG4-RD) is a potentially systemic disease, characterized by high serum IgG4 levels and multi-organ infiltration [1]. All organs and systems may be involved, mimicking many other conditions and more common diseases, such as systemic lupus erythematous, rheumatoid arthritis (RA), or anti-phospholipid syndrome [1].

Involvement of the salivary and lacrimal glands, previously called Mikulicz’s disease, is now reclassified as IgG4-related dacryoadenitis and sialadenitis (IgG4-DA/SA); similarly, Küttner tumour, unilateral swelling of the submandibular gland, is now called IgG4-related submandibular gland disease [2].

Once considered a subtype of Sjögren’s syndrome (SS), these 2 conditions should be also distinguished according to their histological findings. More in detail, IgG4-RD is characterized by tissue fibrosis with a storiform pattern, obliterative vasculitis, tissue eosinophilia, and lymphoplasmacytic infiltration with a prevalence of IgG4-positive plasma-cells and an IgG4/IgG ratio > 40% [3].

It should be stressed that IgG4+ plasma cells can be found in other conditions such as many autoimmune diseases, malignancies, and infections, while the abovementioned histological findings are more specific for IgG4-RD [4].

Nevertheless, differential diagnosis between the primary SS (pSS) and IgG4-RD can be challenging due to their similar clinical presentation; moreover, the coexistence of both IgG4-RD and pSS was also hypothesized and first reported in a Japanese patient fulfilling the diagnostic criteria for both diseases [57].

The aim of our study was to assess the prevalence of IgG4-SA in a cohort of Caucasian patients presenting with xerostomia, and to evaluate the presence of an overlap between IgG4-SA and SS.

Material and methods

A total of n = 154 Italian Caucasian patients (15 ma-les, 139 females) was evaluated. Mean age was 54.18 ±14.24 years. We included all patients who consecutively underwent minor salivary gland biopsy (MSGB) in our department due to suspicion of SS caused by xerostomia, from March to December 2019. Exclusion criteria were active hepatitis C virus, human immunodeficiency virus, tuberculosis, sarcoidosis, end-stage renal disease, and previous head and neck radiotherapy, as well as any sign or symptom of extra-glandular involvement.

We used the punch biopsy technique proposed by Guevara-Gutierrez et al. [8], using a 4-mm punch and 4–0 absorbable sutures, following local anaesthetic infiltration with lidocaine. Salivary gland samples were subsequently fixed in formalin and evaluated by the pathology department of our university using ChisholmMason (CM) and focus score (FS) for SS and immunohistochemical study with IgG4 staining for IgG4-SA.

Histological report was considered putative for SS when CM ≥ 3 and/or FS ≥ 1, putative for IgG4-SA when > 10 IgG4 per high-power field (HPF) were detected, as well as an IgG4/IgG ratio ≥ 40. Anti-nuclear antibodies (ANA), anti-extractable nuclear antigens (ENA) with fluorescent enzyme immunoassay (FEIA), anti-double stranded DNA (dsDNA, FEIA method) antibodies, rheumatoid factor (RF), and anti-citrullinated protein antibodies (ACPA, FEIA method) were concomitantly assessed, as well as serum cryoglobulins and protein electrophoresis.

The American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) classification criteria were used for the definitive diagnosis of pSS [9], and comprehensive criteria by Umehara et al. [10] for IgG4-SA, because, to date, no organ-specific criteria have been proposed [10].

Bioethical standards

All tests performed were related to the routine diagnostics of patients with dryness admitted to our clinic; all patients gave their written informed consent for the procedures. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki.


Anti-nuclear antibodies titre < 1 : 160 was found in 108 patients, 1 : 160 in 12, 1 : 320 in 17, 1 : 640 in 13, > 1 : 640 in 4, and ENA screening was positive (ratio > 1) in 11.7% (n = 18 patients) corresponding to the positivity of anti-Ro/SSA and anti-La/SSB antibodies.

The results of dsDNA (> 15 IU/ml), RF and ACPA (> 7 IU/ml) were positive in 2, 3, and 3 patients, respectively. Only one patient had cryoglobulins (mixed polyclonal, cryocrit 0.5%), while hypergammaglobulinaemia (> 20%) was found in 6 subjects. 44.8% (n = 69) had FS 0, and FS ≥ 1 was found in 55.2% (n = 85), while CM < 3 and CM ≥ 3 were seen in 47.4% (n = 73) and 52.6% (n = 81), respectively.

An IgG4/HPF value of 20 was found in 3 SS patients (1.9%), but an IgG4/IgG ratio ≥ 40 was found in none of them, nor tissue fibrosis with storiform pattern, obliterative vasculitis, or tissue eosinophilia. A definite diagnosis of primary Sjögren’s syndrome (pSS), using histological findings and/or immunological results, was made in 59.74% (n = 92) out of 154 patients who underwent MSGB.

In 3 cases, an overlap between SS and RA was present. The pSS negative group was diagnosed as “nonspecific sicca syndrome” and was not followed up in time. In the 2-year follow-up regarding the pSS-positive group, one case of IgG4 pulmonary-related disease was diagnosed, while one patient developed lymphoma. There were no patients who received a definite diagnosis of IgG4-SA. The obtained data are presented in Table I.

Table I

Demographic, serological autoimmunity, and histopathological data of the patients

VariableNumberPercentage (%)
Demographic data
Age [years ±SD]54.18 ±14.24
Gender15 males/ 139 females9.7/90.3
Autoimmunity data
ANA < 1 : 16010870.1
ANA ≥ 1 : 1604629.9
Hypergammaglobulinaemia (> 20%)63.89
FS = 08555.2
FS ≥ 16944.8
CM score < 37347.4
CM score ≥ 38152.6
20 IgG4/HPF31.9
IgG4/IgG ratio ≥ 4000

[i] ACPA – anti-citrullinated protein antibodies, ANA – anti-nuclear antibodies, CM – Chisholm-Mason score, dsDNA – double stranded DNA, FS – focus score, HPF – high-power field, RF –rheumatoid factor, SD – standard deviation.


To our knowledge, our study represents the first systematic attempt to evaluate IgG4 infiltration in an Italian-based Caucasian cohort of patients who underwent MSGB for xerostomia. In our cohort, 92 patients (59.74%) received a diagnosis of pSS, while none fulfilled the diagnostic criteria for IgG4-SA.

Curiously, one patient, previously diagnosed with pSS, was subsequently evaluated for an interstitial lung disease, and a lung biopsy led to a diagnosis of IgG4-related respiratory disease. Such incidence is notably and surprisingly lower than reported in the Japanese study by Yamamoto et al. [11] in whch 7 of 160 evaluated patients (4.4%) were affected by IgG4-SA, with 6 of them presenting anti-Ro/SSA positivity.

On the other hand, in a Chinese cohort in which an overlap syndrome was suspected, 36 out of 336 pSS patients (10.7%) showed IgG4/IgG ratio ≥ 40% and > 10 IgG4 plasma cells/HPF. Such histological findings were positively associated with interstitial lung disease and tubulointerstitial nephritis, but negatively correlated with anti-Ro/SSA antibodies, anti-La/SSB antibodies, ANA, and RF, showing less lymphocytic infiltration [12].

Moreover, high IgG4 serum levels (> 135 mg/dl) were found in 10 out of 133 pSS patients (7.5%) in a large cohort of Greek patients, and a positive IgG4/IgG ratio (≥ 40%) was found in 3 of 6 high IgG4 serum level subjects who underwent MSGB, leading to a diagnosis of definite IgG4-RD in 3 of 133 pSS patients (2.3%) [13].

An interesting attempt to distinguish between pSS, IgG4-SA, and chronic obstructive sialadenitis was performed by Hong et al. [14] in a cohort of 155 patients. Notably, serum IgG4+ plasma cells were elevated only in the IgG4-SA group (p < 0.001), while anti-SSA/Ro was found only in one patient affected by IgG4-SA [14].

These findings highlight the differences between pSS and IgG4-SA, which, although similar, should be considered 2 distinct entities, and underline the role of anti-SSA/Ro as an exclusion criterion for IgG4-RD, as proposed in the recent ACR/EULAR classification criteria [15].

This underlines that routine research of IgG4 should not be performed in a patient suffering from xerostomia, at least in the European population. Moreover, in our opinion, immunohistochemistry should not be requested in the case of a biopsy negative for pSS: in our cohort, none of the patients with CM < 3 and/or FS < 1 was found to have an IgG4 infiltration.

Despite the lack of a large cross-sectional study, the incidence and prevalence of IgG4-RD is thought to be very low in European countries, and IgG4-SA should also be considered a very unlikely cause of xerostomia among Western populations.

The existence of an overlap syndrome “IgG4-SA/pSS” needs to be better clarified: our data did not provide evidence of any patients with such findings, but only a high number (> 20) of IgG4/HPF in 3 pSS subjects. The clinical and diagnostic meaning of this infiltrate should be better evaluated but cannot be considered enough for a diagnosis of IgG4-SA, as well as an IgG4/IgG ratio ≥ 40.

It should be stressed that tissue fibrosis with storiform pattern, obliterative vasculitis, and tissue eosinophilia remain a fundamental histological feature for the diagnosis of IgG4-SA [4]. If we only consider the presence of IgG4 in a tissue sample, we may not exclude a false positive, being IgG4 described in association to many conditions other than IgG4-RD [1].

Study limitations

Among the limits of our study were the low number of enrolled patients together with the absence of clinical data, except for the presence of xerostomia, disease duration, inflammatory markers, or organ involvement. Although we did not correlate inflammatory markers and salivary gland histopathology, it would be interesting at least to compare serological IgG4 findings with IgG4 salivary gland histopathology.

Another limitation was that no patient presented with submandibular gland swelling. This is probably related to the relatively recent onset of symptoms of the patients who were referred to our centre for MSGB but has probably underrated the incidence of IgG4-SA in our cohort. Submandibular gland swelling is classically defined as a hallmark of IgG4-SA, with patients typically presenting with subacute submandibular and/or parotid swelling [16]. A further limit could be represented by the absence of an imaging exam performed in our cohort.

In a recent paper, Sakamoto et al. [17] showed how salivary gland biopsy has low sensitivity for the diagnosis of IgG4-SA, showing favourable results with ultrasound in identifying IgG4-SA.

However, authors who focused on IgG4-RD highlighted that established features of IgG-RD according to classification criteria [18] and the presence of sialadenitis with correlation with the decreased salivary flow may direct the diagnostic procedures including histopathology assessment of MSGB towards features of IgG4-RD [16, 19].


Our study revealed that minor salivary gland assessment for IgG4 research should not be routinely performed in cases of xerostomia, at least in an Italian- based Caucasian population.

Moreover, immunohistochemistry should not be requested in cases of biopsy negative for pSS.


[2] Conflicts of interest The authors declare no conflicts of interest.



Soliotis F, Mavragani CP, Plastiras SC, et al. IgG4-related disease: a rheumatologist’s perspective. Clin Exp Rheumatol 2014; 32: 724–727.


Stone JH, Khosroshahi A, Deshpande V, et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum 2012; 64: 3061–3067, DOI: 10.1002/art.34593.


Umehara H, Okazaki K, Nakamura T, et al. Current approach to the diagnosis of IgG4-related disease–combination of comprehensive diagnostic and organ-specific criteria. Mod Rheumatol 2017; 27: 381–391, DOI: 10.1080/14397595.2017.1290911.


Puxeddu I, Capecchi R, Carta F, et al. Salivary gland pathology in IgG4-related disease: a comprehensive review. J Immunol Res 2018; 2018: 6936727, DOI: 10.1155/2018/6936727.


McCrary HC, Faucett EA, Erman AB. Immunoglobulin G4-related sclerosing disease mimicking Sjögren’s syndrome: a case report. Laryngoscope 2016; 126: 2242–2245, DOI: 10.1002/lary.26112.


Baer AN, Gourin CG, Westra WH, et al. Rare diagnosis of IgG4-related systemic disease by lip biopsy in an international Sjögren’s syndrome registry. Oral Surg Oral Med Oral Pathol Oral Radiol 2013; 115: e34–e39, DOI: 10.1016/j.oooo.2012.07.485.


Nakashima Y, Nakamura H, Horai Y, et al. Comorbid case of IgG4-related disease and primary Sjögren’s syndrome. Mod Rheumatol 2015; 25: 462–467, DOI: 10.3109/14397595.2013.843750.


Guevara-Gutierrez E, Tlacuilo-Parra A, Minjares-Padilla LM. Mi-nor salivary gland punch biopsy for evaluation of Sjögren’s syndrome. J Clin Rheumatol 2001; 7: 401–402, DOI: 10.1097/00124743-200112000-00010.


Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 2017; 76: 9–16, DOI: 10.1136/annrheumdis-2016-210571.


Umehara H, Okazaki K, Nakamura T, et al. Current approach to the diagnosis of IgG4-related disease–combination of comprehensive diagnostic and organ-specific criteria. Mod Rheumatol 2017; 27: 381–391, DOI: 10.1080/14397595.2017.1290911.


Yamamoto M, Takahashi H, Shinomura Y. Are Sjögren’s syndrome and IgG4-related disease able to coexist? Mod Rheumatol 2015; 25: 970–971, DOI: 10.3109/14397595.2014.948950.


Liu C, Zhang H, Yao G, et al. Characteristics of primary Sjögren’s syndrome patients with IgG4 positive plasma cells infiltration in the labial salivary glands. Clin Rheumatol 2017; 36: 83–88, DOI: 10.1007/s10067-016-3472-x.


Mavragani CP, Fragoulis GE, Rontogianni D, et al. Elevated IgG4 serum levels among primary Sjögren’s syndrome patients: do they unmask underlying IgG4-related disease? Arthritis Care Res (Hoboken) 2014; 66: 773–777, DOI: 10.1002/acr.22216.


Hong X, Li W, Xie XY, et al. Differential diagnosis of IgG4-related sialadenitis, primary Sjögren’s syndrome, and chronic obstructive submandibular sialadenitis. Br J Oral Maxillofac Surg 2017; 55: 179–184, DOI: 10.1016/j.bjoms.2016.10.021.


Wallace ZS, Naden RP, Chari S, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Arthritis Rheumatol 2020; 72: 7–19, DOI: 10.1002/art.41120.


Skillington SA, Ogden MA. IgG4-Related disease and the salivary glands: a review of pathophysiology, diagnosis, and management. Otolaryngol Clin North Am 2021; 54: 497–508, DOI: 10.1016/j.otc.2021.02.002.


Sakamoto M, Moriyama M, Shimizu M, et al. The diagnostic utility of submandibular gland sonography and labial salivary gland biopsy in IgG4-related dacryoadenitis and sialadenitis: its potential application to the diagnostic criteria. Mod Rheumatol 2020 30: 379–384, DOI: 10.1080/14397595.2019.1576271.


Wallace ZS, Naden RP, Chari S, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Arthritis Rheumatol 2020; 72: 7–19, DOI: 10.1002/art.41120.


Doe K, Nozawa K, Okada T, et al. Usefulness of minor salivary gland biopsy in the diagnosis of IgG4-related disease: a case report. Int J Clin Exp Pathol 2014; 7: 2673–2677.

Copyright: © 2022 Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.